The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 29, No. 7, pp. 760-768.
© 1995 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Behbahani, R
Right arrow Articles by Baxter, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Behbahani, R
Right arrow Articles by Baxter, J.


Research Articles

Therapeutic approaches for AIDS-related toxoplasmosis

R Behbahani, M Moshfeghi, and JD Baxter

OBJECTIVE: To summarize current knowledge of prophylaxis and treatment of AIDS-related toxoplasmosis. DATA SOURCES: A MEDLINE search (1985-1994) was used to identify pertinent literature, including reviews. STUDY SELECTION AND DATA EXTRACTION: All articles were considered for possible inclusion in the review. Pertinent information, as judged by the authors, was selected for discussion. DATA SYNTHESIS: Trimethoprim/sulfamethoxazole (TMP/SMX) appears to be useful for prophylaxis against toxoplasmosis in patients with AIDS. The most effective TMP/SMX dose for prevention of toxoplasmosis needs to be determined. Dapsone in combination with pyrimethamine therapy may be an effective alternative for toxoplasmosis prophylaxis. The most effective regimen for the treatment of AIDS-related toxoplasmosis is the combination therapy of pyrimethamine/sulfadiazine. In patients who cannot tolerate sulfadiazine therapy because of adverse effects or allergy, pyrimethamine with clindamycin therapy may be considered as a second-line alternative. Lifelong suppressive therapy is required after either treatment regimen to prevent relapse. Other newer agents such as azithromycin, clarithromycin, atovaquone, or timetrexate-leucovorin need further studies to confirm their true effectiveness in the treatment of toxoplasmosis. CONCLUSIONS: TMP/SMX remains a useful agent in prophylaxis against toxoplasmosis. Pyrimethamine/sulfadiazine is the most effective combination in the treatment of acute toxoplasmosis.


This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
S. A. Klotz, C. C. Penn, G. J. Negvesky, and S. I. Butrus
Fungal and Parasitic Infections of the Eye
Clin. Microbiol. Rev., October 1, 2000; 13(4): 662 - 685.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1995 by Harvey Whitney Books Company.